Valuation: PTC Therapeutics, Inc.

Market Cap 637.22Cr 559.67Cr 520.48Cr 477.61Cr 897.39Cr 61TCr 911.22Cr 6.18TCr 2.41TCr 30TCr 2.39TCr 2.34TCr 1,04300Cr P/E 2026 *
104x
P/E 2027 * 29.6x
Enterprise Value 451.14Cr 396.24Cr 368.49Cr 338.14Cr 635.34Cr 43TCr 645.13Cr 4.38TCr 1.71TCr 21TCr 1.69TCr 1.66TCr 74TCr EV / Sales 2026 *
3.81x
EV / Sales 2027 * 3.29x
Free-Float
92.62%
Yield 2026 *
-
Yield 2027 * -
1 day-2.08%
1 week-2.25%
Current month-5.82%
1 month-9.10%
3 months+12.59%
6 months+2.09%
Current year+1.13%
1 week 76.59
Extreme 76.59
80.56
1 month 76.55
Extreme 76.55
90.87
Current year 61.43
Extreme 61.43
90.87
1 year 43.18
Extreme 43.175
90.87
3 years 17.53
Extreme 17.53
90.87
5 years 17.53
Extreme 17.53
90.87
10 years 4.03
Extreme 4.03
90.87
Manager TitleAgeSince
Chief Executive Officer 54 22/03/2023
Director of Finance/CFO 41 13/07/2023
Chief Tech/Sci/R&D Officer - 01/10/2017
Director TitleAgeSince
Chairman 74 01/11/2004
Chairman 80 31/03/1998
Director/Board Member 65 01/12/2005
Date Insider Type Main position Quantity % Market Cap.
14/07/26 Sell

Chief Financial Officer

-3,494 0.0042%
09/07/26 Fiscal year

Director

47,502 0.0573%
09/07/26 Fiscal year

Chief Technology Officer

7,392 0.0089%
Change 5-day change 1-year change 3-year change Capi.($)
-2.08%-2.25%+71.70%+97.89% 637.22Cr
+0.86%+1.43%+47.17%+161.40% 1,06700Cr
+1.59%+4.09%+56.51%+52.79% 63TCr
+0.95%+1.91%+36.30%+83.13% 46TCr
+1.60%+6.25%+37.00%+30.00% 35TCr
-0.60%+1.52%+36.67%+39.80% 30TCr
-0.14%+0.60%+17.29%+18.19% 26TCr
+0.09%-2.82%-29.09%-41.29% 22TCr
+1.22%+2.66%+22.66%+59.81% 20TCr
-1.18%-3.70%+11.28%+67.43% 16TCr
Average +0.23%+0.97%+30.75%+56.92% 36.5TCr
Weighted average by Cap. +0.76%+1.94%+36.06%+78.18%

Financials

2026 *2027 *
Net sales 118.26Cr 103.87Cr 97Cr 89Cr 166.54Cr 11TCr 169.11Cr 1.15TCr 448.13Cr 5.6TCr 443.95Cr 434.38Cr 19TCr 134.37Cr 118.02Cr 109.76Cr 100.72Cr 189.24Cr 13TCr 192.15Cr 1.3TCr 509.19Cr 6.36TCr 504.44Cr 493.57Cr 22TCr
Net income 5.19Cr 4.56Cr 4.24Cr 3.89Cr 7.32Cr 500.28Cr 7.43Cr 50Cr 20Cr 245.96Cr 20Cr 19Cr 850.4Cr 19Cr 17Cr 16Cr 15Cr 27Cr 1.87TCr 28Cr 188.71Cr 74Cr 921.17Cr 73Cr 71Cr 3.18TCr
Net Debt -186.08Cr -163.43Cr -151.99Cr -139.47Cr -262.05Cr -18TCr -266.09Cr -1.8TCr -705.11Cr -8.81TCr -698.53Cr -683.47Cr -30TCr -194.92Cr -171.2Cr -159.21Cr -146.09Cr -274.5Cr -19TCr -278.73Cr -1.89TCr -738.62Cr -9.23TCr -731.72Cr -715.95Cr -32TCr
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
991
Date Price Change Volume
24/26/24 $76.82 -2.08% 8,38,164
23/26/23 $78.45 +0.06% 7,59,373
22/26/22 $78.40 -0.13% 5,83,883
21/26/21 $78.50 +0.63% 11,45,977
20/26/20 $78.01 -0.74% 9,54,314
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
76.82USD
Average target price
96.07USD
Spread / Average Target
+25.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTCT Stock